Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

Jennifer S. Ko, Patricia Rayman, Joanna Ireland, Shadi Swaidani, Geqiang Li, Kevin D. Bunting, Brian Rini, James H. Finke, Peter A Cohen

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented MDSC accumulation and restored normal T-cell function to the spleens of tumor-bearing mice, independent of the capacity of sunitinib to inhibit tumor progression (RENCA>CT26>4T1). Both monocytic and neutrophilic splenic MDSC were highly repressible by sunitinib. In contrast, MDSC within the microenvironment of 4T1 tumors or human RCC tumors proved highly resistant to sunitinib and ambient T-cell function remained suppressed. Proteomic analyses comparing tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF) predicted sunitinib resistance and recombinant GM-CSF conferred sunitinib resistance to MDSC in vivo and in vitro. MDSC conditioning with GM-CSF uniquely inhibited signal transducers and activators of transcription (STAT3) and promoted STAT5 activation. STAT5ab(null/null) MDSC were rendered sensitive to sunitinib in the presence of GM-CSF in vitro. We conclude that compartment-dependent GM-CSF exposure in resistant tumors may account for the regionalized effect of sunitinib upon host MDSC modulation and hypothesize that ancillary strategies to decrease such regionalized escape will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.

Original languageEnglish (US)
Pages (from-to)3526-3536
Number of pages11
JournalCancer Research
Volume70
Issue number9
DOIs
StatePublished - May 1 2010

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Renal Cell Carcinoma
Neoplasms
Immunologic Factors
T-Lymphocytes
sunitinib
Myeloid-Derived Suppressor Cells
Cellular Microenvironment
Receptor Protein-Tyrosine Kinases
Therapeutic Uses
Transducers
Proteomics
Spleen
Pharmaceutical Preparations
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. / Ko, Jennifer S.; Rayman, Patricia; Ireland, Joanna; Swaidani, Shadi; Li, Geqiang; Bunting, Kevin D.; Rini, Brian; Finke, James H.; Cohen, Peter A.

In: Cancer Research, Vol. 70, No. 9, 01.05.2010, p. 3526-3536.

Research output: Contribution to journalArticle

Ko, Jennifer S. ; Rayman, Patricia ; Ireland, Joanna ; Swaidani, Shadi ; Li, Geqiang ; Bunting, Kevin D. ; Rini, Brian ; Finke, James H. ; Cohen, Peter A. / Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. In: Cancer Research. 2010 ; Vol. 70, No. 9. pp. 3526-3536.
@article{502fb9a518284d8f945c631e8969130c,
title = "Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained",
abstract = "The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented MDSC accumulation and restored normal T-cell function to the spleens of tumor-bearing mice, independent of the capacity of sunitinib to inhibit tumor progression (RENCA>CT26>4T1). Both monocytic and neutrophilic splenic MDSC were highly repressible by sunitinib. In contrast, MDSC within the microenvironment of 4T1 tumors or human RCC tumors proved highly resistant to sunitinib and ambient T-cell function remained suppressed. Proteomic analyses comparing tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF) predicted sunitinib resistance and recombinant GM-CSF conferred sunitinib resistance to MDSC in vivo and in vitro. MDSC conditioning with GM-CSF uniquely inhibited signal transducers and activators of transcription (STAT3) and promoted STAT5 activation. STAT5ab(null/null) MDSC were rendered sensitive to sunitinib in the presence of GM-CSF in vitro. We conclude that compartment-dependent GM-CSF exposure in resistant tumors may account for the regionalized effect of sunitinib upon host MDSC modulation and hypothesize that ancillary strategies to decrease such regionalized escape will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.",
author = "Ko, {Jennifer S.} and Patricia Rayman and Joanna Ireland and Shadi Swaidani and Geqiang Li and Bunting, {Kevin D.} and Brian Rini and Finke, {James H.} and Cohen, {Peter A}",
year = "2010",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-09-3278",
language = "English (US)",
volume = "70",
pages = "3526--3536",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

AU - Ko, Jennifer S.

AU - Rayman, Patricia

AU - Ireland, Joanna

AU - Swaidani, Shadi

AU - Li, Geqiang

AU - Bunting, Kevin D.

AU - Rini, Brian

AU - Finke, James H.

AU - Cohen, Peter A

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented MDSC accumulation and restored normal T-cell function to the spleens of tumor-bearing mice, independent of the capacity of sunitinib to inhibit tumor progression (RENCA>CT26>4T1). Both monocytic and neutrophilic splenic MDSC were highly repressible by sunitinib. In contrast, MDSC within the microenvironment of 4T1 tumors or human RCC tumors proved highly resistant to sunitinib and ambient T-cell function remained suppressed. Proteomic analyses comparing tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF) predicted sunitinib resistance and recombinant GM-CSF conferred sunitinib resistance to MDSC in vivo and in vitro. MDSC conditioning with GM-CSF uniquely inhibited signal transducers and activators of transcription (STAT3) and promoted STAT5 activation. STAT5ab(null/null) MDSC were rendered sensitive to sunitinib in the presence of GM-CSF in vitro. We conclude that compartment-dependent GM-CSF exposure in resistant tumors may account for the regionalized effect of sunitinib upon host MDSC modulation and hypothesize that ancillary strategies to decrease such regionalized escape will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.

AB - The antiangiogenic drug sunitinib is a receptor tyrosine kinase inhibitor with significant, yet not curative, therapeutic effects in metastatic renal cell carcinoma (RCC). Sunitinib is also an immunomodulator, potently reversing myeloid-derived suppressor cell (MDSC) accumulation and T-cell inhibition in the blood even of nonresponder RCC patients. We observed that sunitinib similarly prevented MDSC accumulation and restored normal T-cell function to the spleens of tumor-bearing mice, independent of the capacity of sunitinib to inhibit tumor progression (RENCA>CT26>4T1). Both monocytic and neutrophilic splenic MDSC were highly repressible by sunitinib. In contrast, MDSC within the microenvironment of 4T1 tumors or human RCC tumors proved highly resistant to sunitinib and ambient T-cell function remained suppressed. Proteomic analyses comparing tumor to peripheral compartments showed that granulocyte macrophage colony-stimulating factor (GM-CSF) predicted sunitinib resistance and recombinant GM-CSF conferred sunitinib resistance to MDSC in vivo and in vitro. MDSC conditioning with GM-CSF uniquely inhibited signal transducers and activators of transcription (STAT3) and promoted STAT5 activation. STAT5ab(null/null) MDSC were rendered sensitive to sunitinib in the presence of GM-CSF in vitro. We conclude that compartment-dependent GM-CSF exposure in resistant tumors may account for the regionalized effect of sunitinib upon host MDSC modulation and hypothesize that ancillary strategies to decrease such regionalized escape will enhance the potency of sunitinib as an immunomodulator and a cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=77951754469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951754469&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3278

DO - 10.1158/0008-5472.CAN-09-3278

M3 - Article

C2 - 20406969

AN - SCOPUS:77951754469

VL - 70

SP - 3526

EP - 3536

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -